Evidence map›Paper›PMID 32488419›Full record

SynthesisInternational journal of colorectal disease2020

Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery for patients with locally advanced rectal cancer: a systematic review and meta-analysis.

Shuangwu Feng, Peijing Yan, Qiuning Zhang, Zheng Li, Chengcheng Li, Yichao Geng, Lina Wang, Xueshan Zhao, Zhen Yang, Hongyi Cai and 1 more

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in International journal of colorectal disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Shuangwu FengThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.ORCID https://orcid.org/0000-0001-5272-7840
Peijing YanDepartment of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, 610041, China.
Qiuning ZhangInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou, 730000, China.
Zheng LiInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou, 730000, China.
Chengcheng LiThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Yichao GengThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Lina WangThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Xueshan ZhaoThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Zhen YangSchool of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China.
Hongyi CaiDepartment of Radiation Oncology, Gansu Province People's Hospital, Lanzhou, 730000, China.
Xiaohu WangThe First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China. xhwanggansu@163.com.
Lanzhou University · CNChinese Academy of Sciences · CNGansu Provincial Hospital · CNLanzhou University Second Hospital · CNSichuan University · CN

Funding

Lanzhou Innovation and Entrepreneurship Talent Project 2017- RC-23
6 · The paper itself

Abstract

backgroundControversy persists about whether additional induction chemotherapy (ICT) before neoadjuvant chemoradiation (NCRT) yields improved oncological outcomes. We performed a systematic review and meta-analysis to compare ICT+ NCRT+ surgery(S) with NCRT+ S in patients with locally advanced rectal cancer (LARC).

methodsWe searched the PubMed, EMBASE, Cochrane Library, and China Biology Medicine (CBM) databases. The data were analyzed with Stata version 12.0 software.

resultsWe identified 9 relevant trials that enrolled 1538 patients. We detected no significant difference in the 5-year overall survival (OS) (OR 1.50, 95% CI 0.48-4.64), disease-free survival (DFS) (OR 1.03, 95% CI 0.73-1.46), local recurrence (LR) (OR 0.80, 95% CI 0.45-1.43), and distant metastasis (DM) rates (OR 1.03, 95% CI 0.55-1.93) between patients who did and did not receive ICT. The addition of ICT before NCRT had a similar pathological complete response rate compared to NCRT (OR 1.26, 95% CI 0.90-1.77). Our findings suggest that between the ICT + NCRT+S and NCRT+S groups, ICT improved the incidence of grade 3 to 4 toxicity effects (OR 4.81, 95% CI 2.38-9.37), but between the ICT + NCRT+S and NCRT+S+ adjuvant chemotherapy (ACT) groups, ICT might reduce toxicity (OR 0.19, 95% CI 0.08-0.50). ICT had no significant impact on surgical complications (OR 0.97, 95% CI 0.63-1.51).

conclusionsThe addition of ICT before NCRT seemingly shows no survival benefit on patients with LARC, and might increase the toxicity.

Indexed as

Neoadjuvant TherapyRectal NeoplasmsChemoradiotherapyChemoradiotherapy, AdjuvantChinaHumansInduction ChemotherapyNeoplasm Recurrence, LocalTreatment OutcomeInduction chemotherapyMeta-analysisNeoadjuvant therapyRectal cancerSystematic review

Identifiers

PMID32488419
OpenAlexW3029954454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.